LEXX

Lexaria Bioscience Corp

Apr 08 • 04:00PM ET

0.9552

-0.0348 -3.52 %

Healthcare • Biotechnology • Canada • NASD

Apr 02, 8:30 PMNew human GLP-1 pilot study contract signing fuels continued buying momentum.

Peers: TLRY CRON IIPR TVRD CGC ACB OGI VFF APH OGEN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	5.36%	Shs Outstand	24.89M	Perf Week	22.46%
Market Cap	23.77M	Forward P/E	-	EPS next Y	-0.31	Insider Trans	0.00%	Shs Float	23.55M	Perf Month	30.94%
Enterprise Value	19.06M	PEG	-	EPS next Q	-0.07	Inst Own	6.84%	Short Float	1.58%	Perf Quarter	36.28%
Income	-10.79M	P/S	45.71	EPS this Y	60.61%	Inst Trans	-0.11%	Short Ratio	2.02	Perf Half Y	13.71%
Sales	0.52M	P/B	4.32	EPS next Y	-19.23%	ROA	-136.24%	Short Interest	0.37M	Perf YTD	54.81%
Book/sh	0.22	P/C	5.38	EPS next 5Y	24.86%	ROE	-146.97%	52W High	1.69 -43.48%	Perf Year	-28.18%
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	18.80% 14.15%	ROIC	-216.57%	52W Low	0.46 107.65%	Perf 3Y	-59.70%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	40.34% 17.53%	Gross Margin	84.90%	Volatility	13.40% 10.99%	Perf 5Y	-82.79%
Dividend TTM	-	EV/Sales	36.65	EPS Y/Y TTM	-17.41%	Oper. Margin	-2021.04%	ATR (14)	0.09	Perf 10Y	-70.22%
Dividend Ex-Date	-	Quick Ratio	3.68	Sales Y/Y TTM	5.05%	Profit Margin	-2067.65%	RSI (14)	63.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.68	EPS Q/Q	54.01%	SMA20	19.67%	Beta	0.58	Target Price	6.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	28.67%	Rel Volume	0.74	Prev Close	0.99
Employees	7	LT Debt/Eq	0.01	Earnings	Jan 21	SMA200	7.90%	Avg Volume	184.35K	Price	0.96
IPO	Oct 10, 2006	Option/Short	No / Yes	EPS/Sales Surpr.	46.15% -100.00%	Trades		Volume	137,187	Change	-3.52%

Apr-07-26 09:10AM	Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval (ACCESSWIRE) -6.60%
Apr-01-26 09:20AM	Lexaria to Begin New Human Clinical Study in GLP-1 (ACCESSWIRE) +11.04%
Mar-26-26 09:20AM	Lexaria's Robust Patent Portfolio Continues to Grow (ACCESSWIRE)
Mar-24-26 09:15AM	Lexaria's Oral GLP-1 Drug Strategy Validated by Industry (ACCESSWIRE) +7.12%
Mar-04-26 09:25AM	Lexaria Announces New R&D Plans for 2026 (ACCESSWIRE) +5.04%
09:15AM	Loading…
Feb-05-26 09:15AM	Lexaria Announces Positive Final Results From Human Pilot Study #5 (ACCESSWIRE) -8.66%
Jan-22-26 09:20AM	Lexaria Awarded Six Additional Patents (ACCESSWIRE)
Jan-12-26 09:10AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Dec-31-25 09:25AM	Lexaria releases additional results from Phase 1b study GLP-1-H24-4 (TipRanks) +13.46%
Dec-30-25 09:20AM	Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 (ACCESSWIRE)
Dec-23-25 09:29AM	Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 (ACCESSWIRE) -8.01%
Dec-16-25 04:00PM	Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -5.62% -18.86%
Dec-15-25 08:00AM	Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -33.58%
Nov-12-25 09:10AM	Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended (ACCESSWIRE)
Oct-09-25 09:20AM	Lexaria Bioscience Corp. Provides Strategic Update (ACCESSWIRE)
04:30PM	Loading…
Sep-29-25 04:30PM	Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -6.40%
Sep-26-25 08:00AM	Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -31.37%
Sep-19-25 11:20AM	Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain (ACCESSWIRE)
Aug-27-25 09:20AM	Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference (ACCESSWIRE)
Aug-15-25 09:25AM	Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study (TipRanks)
Aug-14-25 09:20AM	Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone (ACCESSWIRE)
Aug-06-25 09:20AM	GLP-1 "Arms Race" Broadens to Include Dozens of Companies (ACCESSWIRE)
Jul-28-25 09:25AM	Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study (ACCESSWIRE) -8.49%
Jul-23-25 09:25AM	Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry (ACCESSWIRE) +6.19%
Jun-23-25 09:15AM	Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide (ACCESSWIRE)
Jun-12-25 09:15AM	Lexaria Bioscience announces completion of GLP-1-H25-5 study (TipRanks)
Jun-11-25 09:05AM	Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule (ACCESSWIRE)
Jun-05-25 09:20AM	Lexaria Attending BIO International Convention (ACCESSWIRE)
May-12-25 09:00AM	Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company (ACCESSWIRE)
Apr-28-25 04:15PM	Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -9.63%
08:00AM	Loading…
Apr-25-25 08:00AM	Lexaria Announces $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -20.12%
Apr-23-25 09:10AM	Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology (ACCESSWIRE) +8.90%
Apr-03-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) -8.38%
Mar-18-25 09:15AM	Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) (ACCESSWIRE) -5.25%
Feb-27-25 08:00AM	The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience (ACCESSWIRE)
Feb-24-25 08:00AM	Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm (ACCESSWIRE) +5.52%
Feb-20-25 08:00AM	Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide (ACCESSWIRE) -10.06%
Feb-11-25 08:00AM	Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy (ACCESSWIRE) -5.29%
Feb-06-25 09:40AM	Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway (ACCESSWIRE)
Feb-05-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) +5.08%
Jan-30-25 09:15AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-15-25 09:20AM	Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval (ACCESSWIRE)
Jan-14-25 09:10AM	Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R) (ACCESSWIRE) -6.31%
Dec-19-24 09:05AM	Lexaria's Registered GLP-1 Study #4 Begins Dosing (ACCESSWIRE)
Dec-18-24 09:25AM	Lexaria Forms New Scientific Advisory Board (ACCESSWIRE)
Dec-17-24 09:10AM	Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience (ACCESSWIRE)
Dec-10-24 09:43AM	Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide (TipRanks)
Dec-09-24 09:10AM	Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 (ACCESSWIRE)
Nov-30-24 11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, and Surge Battery Metals (Newsfile)
11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals (Newsfile)
Nov-26-24 09:20AM	Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs (ACCESSWIRE)
Nov-25-24 09:00AM	Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled (ACCESSWIRE)
Nov-20-24 09:05AM	ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study (ACCESSWIRE)
Nov-14-24 09:10AM	Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study (ACCESSWIRE) -6.19%
Nov-13-24 09:20AM	Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss (ACCESSWIRE)
Nov-07-24 09:15AM	Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments (ACCESSWIRE) +5.94%
Oct-24-24 09:10AM	Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-22-24 09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-16-24 04:00PM	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Oct-15-24 08:25AM	Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -6.21%
Oct-09-24 09:05AM	Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (ACCESSWIRE)
Oct-08-24 09:20AM	Lexaria Updates Current GLP-1 Market (ACCESSWIRE)
Oct-01-24 09:25AM	Lexaria Appoints Michael Shankman as Chief Financial Officer (ACCESSWIRE)
Sep-27-24 09:20AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 (ACCESSWIRE)
Sep-05-24 10:00AM	Lexaria Releases Strategic Letter from the Outgoing CEO (ACCESSWIRE)
09:00AM	Lexaria Welcomes Industry Veteran as New CEO (ACCESSWIRE)
Sep-03-24 08:30AM	Lexaria Enters a Material Transfer Agreement for DehydraTECH Research (ACCESSWIRE) -6.65%
Aug-29-24 09:25AM	Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules (ACCESSWIRE) +10.62%
Aug-27-24 09:20AM	First Results from Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Aug-22-24 09:20AM	Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE) -7.90%
Aug-21-24 09:00AM	Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Aug-19-24 09:05AM	Positive Results from Lexaria's Molecular Characterization Study (ACCESSWIRE)
Jul-17-24 10:30AM	Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study (ACCESSWIRE)
Jul-16-24 09:20AM	Lexaria Preparing For Strategic Growth (ACCESSWIRE)
Jul-12-24 05:52PM	LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
Jul-09-24 09:10AM	Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jul-08-24 09:10AM	Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy (ACCESSWIRE) -5.49%
Jun-24-24 06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-18-24 09:00AM	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study (ACCESSWIRE)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.08%
Jun-05-24 09:00AM	Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-30-24 06:45AM	7 A-Rated Penny Stocks Work Betting On in H2 2024 (InvestorPlace) +5.00%
May-23-24 09:05AM	Lexaria Awards Contract For Third GLP-1 Human Pilot Study (ACCESSWIRE)
May-21-24 09:20AM	Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy (ACCESSWIRE)
May-17-24 09:10AM	Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study (ACCESSWIRE)
May-08-24 09:10AM	Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study (ACCESSWIRE)
May-06-24 09:05AM	Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs (ACCESSWIRE) +8.95%
Apr-30-24 03:40PM	Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance (ACCESSWIRE) +25.61%
Apr-16-24 09:10AM	Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study (ACCESSWIRE) +16.08%
Apr-09-24 09:52PM	LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024 (InvestorPlace) -8.78%
Apr-02-24 09:00AM	Lexaria Awarded New Patents (ACCESSWIRE)
Mar-21-24 09:20AM	Lexaria to Present at The LD Micro Invitational XIV (Newsfile) -7.03%
Mar-14-24 09:20AM	Lexaria Appoints Nelson Cabatuan as Chief Financial Officer (ACCESSWIRE) -12.50%
Mar-07-24 09:05AM	Lexaria Awards Contract For Next GLP-1 Human Pilot Study (ACCESSWIRE) +11.61%
Mar-05-24 09:05AM	Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 (ACCESSWIRE) +12.67%
Mar-04-24 09:15AM	7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study (ACCESSWIRE)
Mar-01-24 08:20AM	Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE) -15.36%
Feb-16-24 04:05PM	Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.32% +8.41%
Feb-15-24 08:00AM	Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.23%

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUNKA CHRISTOPHER	Director	Jul 29 '25	Buy	0.92	15,600	14,375	270,012	Jul 30 05:12 PM
BUNKA CHRISTOPHER	Director	Jul 30 '25	Buy	0.91	11,900	10,866	281,912	Jul 30 05:12 PM
McKechnie William Edward	Director	Jul 29 '25	Buy	0.91	5,000	4,532	18,191	Jul 30 12:37 PM
DOCHERTY JOHN MARTIN	President & CSO	Jul 29 '25	Buy	0.93	5,376	4,989	5,376	Jul 30 11:34 AM
Carle Vanessa	Secretary	Jul 29 '25	Buy	0.91	750	682	750	Jul 30 11:23 AM
CHRISTOPHER RICHARD	Chief Executive Officer	Jul 29 '25	Buy	0.91	15,000	13,641	65,000	Jul 30 11:14 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LEXX

Lexaria Bioscience Corp

Upgrade your Finviz experience